OVV-CXCR4-A-Fc

OVV-CXCR4-A-Fc is an experimental oncolytic virotherapy consisting of an oncolytic vaccinia virus (OVV) engineered to express a CXCR4 antagonist fused to the Fc portion of murine IgG2a. Developed at the Roswell Park Comprehensive Cancer Center, this biologic therapy targets the CXCL12/CXCR4 axis, which is often exploited by tumors for metastasis and immune evasion. The virus selectively replicates within cancer cells, causing direct oncolysis while simultaneously delivering the CXCR4 antagonist to the tumor microenvironment. This dual approach aims to inhibit the recruitment of immunosuppressive cells, disrupt tumor-associated vasculature, and stimulate a robust antitumor immune response. Preclinical studies have investigated its efficacy in chemoresistant ovarian cancer, metastatic breast cancer, and neuroblastoma.